Home › OncoGenex Is A Buy As Thesis Remains Intact
 

Keywords :   


OncoGenex Is A Buy As Thesis Remains Intact

2015-05-26 15:22:15| Logistics - Topix.net

In addition to the potential for news at ASCO and the company call discussing the data after the event, the second futility analysis for ENSPIRIT provides near-term upside potential. With over $40 million in cash at Q1 end and greater than $23 million recently received from Teva, OncoGenex is grossly undervalued at its current sub-$45 million market cap.

Tags: buy remains thesis intact

Category:Transportation and Logistics

Latest from this category

All news
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
25.06Atlantic Tropical Weather Outlook
25.06Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
26.06Horizon expert 'gave evidence based on informal chats'
26.06Automotive Color by BASF Recognized with Renowned Red Dot Award
26.06Beckers Commits to Widespread Science Based Targets
26.06PPG to Announce Second-quarter 2024 Results July 18
26.06Fresh Coat for First Responders: New Hampshire Fire Station Gets a Makeover by California Paints
26.06Michigan Sets Record Recycling Rate in 2023, Recycles Nearly 70,000 Tons of Materials
26.06Companies Seek Federal EPR: How Producers Can Prepare
26.06Q&A with GFLs Tyler Stefure: Integrating New Fleet Tech & Upholding GFL Values
More »